Clear Vision for Healthcare Investing
Copyright © 2015 Clarus Ventures, LLC - All Rights Reserved
Achillion is a biopharmaceutical company focused on the discovery, development, and commercialization of novel, small molecule inhibitors targeting infectious disease. Pipeline programs include a first-in-class HCV replicase inhibitor partnered with Gilead and an HCV protease inhibitor. Additional drug candidates target treatment of HIV and bacterial infections.
Aerie Pharmaceuticals is a privately held, clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma. Aerie’s internal research and development engine has generated an innovative glaucoma pipeline. In addition to AR-12286, the Company’s Rho-kinase (ROCK) inhibitor, the pipeline includes AR-13165, a novel product candidate with a dual mechanism of action that represents the first of a new proprietary class of glaucoma drugs. AR-13165 is currently in preclinical, IND-enabling studies.
Annexon is developing novel antibody therapeutics for neurodegenerative and autoimmune disorders. Annexon’s most advanced program targets Huntington’s disease
Avanir Pharmaceuticals (Nasdaq:AVNR) is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. Avanir’s products and product candidates address therapeutic markets that include central nervous system disorders, inflammation, and infectious disease. Zenvia™ is Avanir's lead product candidate for the treatment of pseudobulbar affect (PBA), also known as involuntary emotional expression disorder (IEED).
Avillion is a drug development company with an innovative business model for the clinical development and approval of late stage pharmaceutical products. We offer a compelling opportunity to partner late phase therapeutic projects for approval in the EU and US and to accelerate their availability to the market.
Catabasis is an early stage biopharmaceutical company led by experienced entrepreneurs that is developing NCEs that incorporate, and amplify the beneficial effects of, OMEGA-3 fatty acids. It is advancing multiple proprietary small molecule candidates for the treatment of metabolic disease and inflammation.
Cleave Biosciences is an early stage oncology therapeutics
company focused on novel targets in cellular protein homeostasis pathways.
Controlled largely by two distinct systems – the ubiquitin proteasome system
and the autophagy system, these pathways are utilized by cancer cells for their
growth and survival.
The company secured a $42M Series A investment in
CoMentis, Inc. is engaged in the discovery and development of small-molecule drugs to treat neurovascular disease indications, such as Alzheimer’s disease, AMD and cognitive disorders. The company has two fundamental technology platforms: (i) beta-secretase inhibitors for the treatment of Alzheimer’s disease; and (ii) nACh receptor agonists and antagonists for the treatment of angiogenesis mediated diseases and cognitive disorders.
Delenex Therapeutics AG is a Swiss biotech company developing antibody fragments for local/topical treatment of chronic and systemic treatment of acute diseases. Delenex was spun-off from ESBATech before its acquisition by Alcon in September 2009
Edev is a special purpose vehicle that has entered into an R&D project financing relationship with an undisclosed pharma company to finance multiple Phase 3 clinical trials
for additional indications of an already-approved drug.
Privately-held ESBATech AG is a Zurich, Switzerland based drug discovery and development company focused on advancing antibody fragments for therapeutic applications.
FerroKin Biosciences Inc., a San Carlos, Calif.-based company, is developing an iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. Clarus Ventures has co-invested with Burrill & Co. and Celgene Inc.
Flowonix Medical is focused on developing better treatment options for the 75 million Americans in chronic pain, more than diabetes, heart disease, and cancer combined. Our first product for delivery of intrathecal medication, the Prometra® programmable implantable pump, is undergoing clinical trials. Flowonix is headquartered in Mount Olive, NJ.
Globus Medical, Inc. is focused on the development of products that enable spine surgeons to employ both fusion and non-fusion solutions to promote healing in patients with spinal disorders. Today Globus is one of the fastest growing spinal implant companies in the world and a recognized leader in the development of motion sparing technology.
Heptares is a drug discovery company focused on the discovery of novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs). The Company is deploying its proprietary StaR™ technology principally against highly validated but currently difficult or intractable GPCR targets in several disease areas.
Imago BioSciences is a San Francisco-based clinical development company dedicated to translating state-of-the art science into novel medicines for treating diseases that currently pose great challenges to patients, their families and their physicians. The company leverages the skills and extensive experience of its team and the financial commitment of its investors to focus on a small family of orphan diseases. Imago BioSciences translates unique insights into high impact transformative therapies that alter the natural history of disease allowing patients to live longer, disease-free lives.
Imago BioSciences Website
Imbruvica is an oral BTK-inhibitor currently under development by Pharmacyclics and J&J for a wide variety of B-cell malignancies, including chronic lymphocytic leukemia(CLL) and mantle cell lymphoma (MCL). It is currently in 8 pivotal trials and multiple Ph 2 trials for various relapsed/refractory and front line settings. The drug has been granted three breakthrough designations by the FDA and was approved for relapsed/refractory MCL in November 2013.
Intercept is focused on the development and commercialization of novel, small molecule therapeutics to treat chronic liver disease by leveraging its expertise in bile acid
chemistry. Its lead candidate, obaticholic acid (OCA), is an FXR agonist
that is currently in pivotal trials for primary biliary cirrhosis (PBC), a
chronic autoimmune liver disease. OCA has received orphan designation for
PBC in both the US and Europe. OCA is also being evaluated in an
NIH-sponsored trial for non-alcoholic steatohepatitis (NASH).
Link Medicine is advancing disease-modifying technologies targeted at Alzheimer's, Parkinson's and other neurodegenerative diseases where current symptomatic therapies are limited in efficacy or duration, and at orphan indications which lack any meaningful symptomatic treatments.
Lycera is an early stage biotechnology company developing first in class small molecule drugs for the treatment of autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease. Lycera’s pipeline includes proprietary small molecules against two novel targets, a mitochondrial molecule that is central to lymphocyte bioenergetics and a nuclear hormone receptor that modulates the Th17 pathway. Lycera’s small molecule drugs have the potential for best in class oral efficacy without the adverse effects of current immunosuppressive agents.
Nanostring is a commercial stage company and an emerging leader in the expression profiling market. Its lead product is the only system capable of highly multiplexed direct quantification of individual mRNAs in a biological sample without the use of enzymes or amplification. With sensitivity below a single copy of mRNA per cell, high accuracy, robust output, and simplified workflow, the Nanostring platform offers investigators the benefits of the accuracy of PCR with the ability to interrogate more genes (up to a thousand) that would traditionally not be possible with PCR . Unlike PCR or microarrays, the Nanostring technology affords digital results by directly imaging and counting mRNAs on solid support.
Neomend, Inc. based in Irvine, CA has developed advanced surgical sealant, adhesion barrier, and applicator technologies based on its proprietary protein and polymer based hydrogel platform. Targeted surgical procedures include thoracic, spine, gynecology and general surgery. The company's initial product, ProGELTM Pleural Air Leak Sealant, has received FDA PMA approval and is the only indicated surgical sealant in the U.S. for sealing lung air leaks in thoracic surgery. ProGEL showed statistically significant reductions in intra-operative air leaks and length of hospital stay days in the PMA trial.
Neothetics is a clinical-stage company developing therapeutics for the aesthetics market. Their initial focus is on non-surgical localized fat reduction and body contouring. The Company’s lead drug candidate is for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. The Company has completed Phase 2 development for LIPO-202 and plans to launch Phase 3 trials in early 2015.
Nuvelution leverages its extensive knowledge, experience and
relationships in the Pharma and Biotech industries to deploy capital in
risk-sharing collaborations with companies where product development can be
facilitated by both capital and human resources with the goal of making this model an essential tool for pharma and biotech companies to bring products to the market.
Ophthotech Corporation is a privately-held, clinical-stage biotechnology company focused on developing and commercializing therapies for both wet and dry Age-Related Macular Degeneration (AMD). Three new molecular entities are currently in clinical development: E10030, an anti-platelet-derived growth factor (PDGF) pegylated aptamer; ARC1905, a pegylated aptamer targeting the C5 component of the complement cascade; and Volociximab, a monoclonal antibody targeting the transmembrane receptor α5β1 integrin. All three Ophthotech drug products are currently in a phase 1 clinical trial for combination treatment with anti-VEGF therapy (Lucentis®). The most advanced product, E10030, has completed a Phase 1 trial.
Oxford Immunotec Ltd develops and sells clinical diagnostic products based on its patented, regulatory approved T-SPOT® technology. T-SPOT is a novel platform technology that opens up new ways of diagnosing and monitoring infections by providing a simple and extremely accurate method of studying a person’s cellular immune response to an infection. Oxford Immunotec’s first product T-SPOT®.TB, is a revolutionary new blood test for diagnosing Tuberculosis infection, offering unmatched sensitivity.
Pearl Therapeutics, Inc. is a privately-held company focused on improving the treatment and prevention of widely prevalent respiratory disorders. Pearl has licensed a suite of particle technologies from Nektar Therapeutics, Inc. to rapidly advance their product candidates through development.
Restoration Robotics, Inc., a privately held medical device company, is dedicated to revolutionizing the field of hair transplantation by developing and commercializing a state-of-the-art image-guided system (ARTAS™ System) that enables follicular unit extraction.
Restoration Robotics Website
SARcode is a private, San Francisco based company focused on the development of small molecule LFA-1 inhibitors to treat inflammatory diseases. In December, 2006 SARcode secured $25 million in a financing co-led by Clarus Ventures and Alta Partners.
SFJ Pharmaceuticals (SanFrancisco/Japan) serves as a clinical development specialty pharma company with a focus on obtaining product approval in Japan. Targeted candidates for development in Japan are low risk compounds that are already approved or have a high likelihood of approval in the US with projected Japan annual sales in excess of $100M. To date, SFJ has entered definitive agreements with two major global pharma companies to fund Phase 3 trials for oncology assets. Pre-determined milestone payments to SFJ shall be received on approval of the asset in pre-specified countries.
SFJ Pharmaceuticals Website
Sientra is a private medical device company focused on developing and marketing a broad portfolio of products within the rapidly growing plastic surgery and aesthetics market. In April 2007, Sientra secured $85 million in a Series B financing co-led by Clarus Ventures.
Taligen is a biopharmaceutical company focused on developing inhibitors of the complement system for a variety of therapeutic indications.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company founded on a mechanism that has the potential to promote apoptosis, or programmed cell death, in cancer cells. Cancer cells are often resistant to apoptosis and Tetralogic’s lead molecule, a Smac-mimetic, may abrogate that resistance. The Smac-mimetic is currently in clinical trials for the treatment of cancer.
TyRx develops and commercializes proprietary, polymer-based, antibiotic-eluting medical products that prevent infection and capsular scar formation, two common morbidities associated with medical device implants.It currently has 3 FDA approved products including AIGIS CRMD, an antibiotic-eluting mesh envelope to prevent infections associated with the implantation of cardiac rhythm management devices (CRMDs) such as pacemakers and implantable defibrillators. The company launched AIGIS CRMD in the US in Q3 2008 with its own specialty sales force.
VBI is dedicated to the innovative formulation,development and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets. VBI’s innovative approach to vaccine development and growing pipeline address clear market opportunities and are designed to answer critical unmet medical needs
VBI is aprivately held company headquartered in Cambridge, Massachusetts, with research facilities in Ottawa, Canada.
Virdante Pharmaceuticals is developing safer and more effective drugs for autoimmune and inflammatory diseases. Our products incorporate a proprietary “sialic switch” technology to improve the anti-inflammatory properties of antibodies.
Zogenix, Inc. is a specialty pharmaceutical company focused on the development and commercialization of medicines to treat CNS disorders and pain. Zogenix’ initial focus is the late-stage development and commercialization of Intraject® sumatriptan -- a needle-free, single-use, disposable, subcutaneous delivery system that will compete in the $2.5 billion triptan segment of the migraine market. In August, 2006, Zogenix secured $60 million in a financing co-led by Clarus Ventures.